Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
Status:
Active, not recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
This is a pilot randomized controlled trial examining the feasibility of conducting a large
scale randomized controlled trial of belatacept-based immunosuppression in lung
transplantation. This pilot study will enroll 40 lung transplant recipients and randomize
them to belatacept-based immunosuppression or standard of care. The primary endpoint of the
study is the development of donor-specific HLA antibodies after transplantation. All study
participants will be followed for a minimum of 12 months after transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Bristol-Myers Squibb National Heart, Lung, and Blood Institute (NHLBI)